Oliver K Jawitz1, Brian C Gulack2, Maria V Grau-Sepulveda3, Roland A Matsouaka3, Michael J Mack4, David R Holmes5, John D Carroll6, Vinod H Thourani7, J Matthew Brennan8. 1. Department of Surgery, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Durham, North Carolina. Electronic address: oliver.jawitz@duke.edu. 2. Department of Surgery, SickKids, Toronto, Ontario, Canada. 3. Duke Clinical Research Institute, Durham, North Carolina. 4. Department of Cardiovascular Disease, Baylor Scott and White Health, Plano, Texas. 5. Department of Cardiovascular Diseases, Mayo Clinic Health System, Minneapolis, Minnesota. 6. Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado. 7. Department of Cardiovascular Surgery, Marcus Heart and Vascular Center, Piedmont Heart and Vascular Institute, Atlanta, Georgia. 8. Department of Medicine, Duke University Medical Center, Durham, North Carolina.
Abstract
OBJECTIVES: This study sought to report the largest series of patients receiving a surgical reoperation after transcatheter aortic valve replacement (TAVR) using the Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database. BACKGROUND: TAVR has become an effective means of treating aortic stenosis. As TAVR is used in progressively lower-risk cohorts, management of device failure will become increasingly important. METHODS: The STS Adult Cardiac Surgery Database was queried for patients with a history of prior TAVR undergoing surgical aortic valve replacement from 2011 to 2015. Observed-to-expected (O/E) mortality ratios were determined to facilitate comparison across reoperative indications and timing from index TAVR procedure. RESULTS: A total of 123 patients met inclusion criteria (median age 77 years) with an STS Predicted Risk of Mortality of 4%, 4% to 8%, and >8% in 17%, 24%, and 59%, respectively. Median time to reoperation was 2.5 (interquartile range: 0.7 to 13.0) months, and the operative mortality rate was 17.1%. Common indications for reoperation included early TAVR device failures such as paravalvular leak (15%), structural prosthetic deterioration (11%), failed repair (11%), sizing or position issues (11%), and prosthetic valve endocarditis (10%). All pre-operative risk categories were associated with an increased O/E mortality ratio (Predicted Risk of Mortality <4%: O/E 5.5; 4% to 8%: O/E 1.7; >8%: O/E 1.2). CONCLUSIONS: SAVR following early failure of TAVR, while rare, is associated with worse-than-expected outcomes as compared with similar patients initially undergoing SAVR. Continued experience with this developing technology is needed to reduce the incidence of early TAVR failure and further define optimal treatment of failed TAVR prostheses.
OBJECTIVES: This study sought to report the largest series of patients receiving a surgical reoperation after transcatheter aortic valve replacement (TAVR) using the Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database. BACKGROUND: TAVR has become an effective means of treating aortic stenosis. As TAVR is used in progressively lower-risk cohorts, management of device failure will become increasingly important. METHODS: The STS Adult Cardiac Surgery Database was queried for patients with a history of prior TAVR undergoing surgical aortic valve replacement from 2011 to 2015. Observed-to-expected (O/E) mortality ratios were determined to facilitate comparison across reoperative indications and timing from index TAVR procedure. RESULTS: A total of 123 patients met inclusion criteria (median age 77 years) with an STS Predicted Risk of Mortality of 4%, 4% to 8%, and >8% in 17%, 24%, and 59%, respectively. Median time to reoperation was 2.5 (interquartile range: 0.7 to 13.0) months, and the operative mortality rate was 17.1%. Common indications for reoperation included early TAVR device failures such as paravalvular leak (15%), structural prosthetic deterioration (11%), failed repair (11%), sizing or position issues (11%), and prosthetic valve endocarditis (10%). All pre-operative risk categories were associated with an increased O/E mortality ratio (Predicted Risk of Mortality <4%: O/E 5.5; 4% to 8%: O/E 1.7; >8%: O/E 1.2). CONCLUSIONS: SAVR following early failure of TAVR, while rare, is associated with worse-than-expected outcomes as compared with similar patients initially undergoing SAVR. Continued experience with this developing technology is needed to reduce the incidence of early TAVR failure and further define optimal treatment of failed TAVR prostheses.
Authors: Selami Dogan; Omer Dzemali; Gerhard Wimmer-Greinecker; Patrick Derra; Mirko Doss; Mohammad F Khan; Tayfun Aybek; Peter Kleine; Anton Moritz Journal: J Heart Valve Dis Date: 2003-01
Authors: Martin B Leon; Craig R Smith; Michael Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; David L Brown; Peter C Block; Robert A Guyton; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Pamela S Douglas; John L Petersen; Jodi J Akin; William N Anderson; Duolao Wang; Stuart Pocock Journal: N Engl J Med Date: 2010-09-22 Impact factor: 91.245
Authors: Vinod H Thourani; Susheel Kodali; Raj R Makkar; Howard C Herrmann; Mathew Williams; Vasilis Babaliaros; Richard Smalling; Scott Lim; S Chris Malaisrie; Samir Kapadia; Wilson Y Szeto; Kevin L Greason; Dean Kereiakes; Gorav Ailawadi; Brian K Whisenant; Chandan Devireddy; Jonathon Leipsic; Rebecca T Hahn; Philippe Pibarot; Neil J Weissman; Wael A Jaber; David J Cohen; Rakesh Suri; E Murat Tuzcu; Lars G Svensson; John G Webb; Jeffrey W Moses; Michael J Mack; D Craig Miller; Craig R Smith; Maria C Alu; Rupa Parvataneni; Ralph B D'Agostino; Martin B Leon Journal: Lancet Date: 2016-04-03 Impact factor: 79.321
Authors: Alain Cribier; Helene Eltchaninoff; Assaf Bash; Nicolas Borenstein; Christophe Tron; Fabrice Bauer; Genevieve Derumeaux; Frederic Anselme; François Laborde; Martin B Leon Journal: Circulation Date: 2002-12-10 Impact factor: 29.690
Authors: Michael J Mack; Martin B Leon; Craig R Smith; D Craig Miller; Jeffrey W Moses; E Murat Tuzcu; John G Webb; Pamela S Douglas; William N Anderson; Eugene H Blackstone; Susheel K Kodali; Raj R Makkar; Gregory P Fontana; Samir Kapadia; Joseph Bavaria; Rebecca T Hahn; Vinod H Thourani; Vasilis Babaliaros; Augusto Pichard; Howard C Herrmann; David L Brown; Mathew Williams; Jodi Akin; Michael J Davidson; Lars G Svensson Journal: Lancet Date: 2015-03-15 Impact factor: 79.321
Authors: Michael J Reardon; Nicolas M Van Mieghem; Jeffrey J Popma; Neal S Kleiman; Lars Søndergaard; Mubashir Mumtaz; David H Adams; G Michael Deeb; Brijeshwar Maini; Hemal Gada; Stanley Chetcuti; Thomas Gleason; John Heiser; Rüdiger Lange; William Merhi; Jae K Oh; Peter S Olsen; Nicolo Piazza; Mathew Williams; Stephan Windecker; Steven J Yakubov; Eberhard Grube; Raj Makkar; Joon S Lee; John Conte; Eric Vang; Hang Nguyen; Yanping Chang; Andrew S Mugglin; Patrick W J C Serruys; Arie P Kappetein Journal: N Engl J Med Date: 2017-03-17 Impact factor: 91.245
Authors: Kazuyuki Yahagi; Sho Torii; Elena Ladich; Robert Kutys; Maria E Romero; Hiroyoshi Mori; Frank D Kolodgie; Jeffrey J Popma; Renu Virmani; Aloke V Finn Journal: Catheter Cardiovasc Interv Date: 2017-09-12 Impact factor: 2.692
Authors: Martin B Leon; Craig R Smith; Michael J Mack; Raj R Makkar; Lars G Svensson; Susheel K Kodali; Vinod H Thourani; E Murat Tuzcu; D Craig Miller; Howard C Herrmann; Darshan Doshi; David J Cohen; Augusto D Pichard; Samir Kapadia; Todd Dewey; Vasilis Babaliaros; Wilson Y Szeto; Mathew R Williams; Dean Kereiakes; Alan Zajarias; Kevin L Greason; Brian K Whisenant; Robert W Hodson; Jeffrey W Moses; Alfredo Trento; David L Brown; William F Fearon; Philippe Pibarot; Rebecca T Hahn; Wael A Jaber; William N Anderson; Maria C Alu; John G Webb Journal: N Engl J Med Date: 2016-04-02 Impact factor: 91.245
Authors: Reed A Siemieniuk; Thomas Agoritsas; Veena Manja; Tahira Devji; Yaping Chang; Malgorzata M Bala; Lehana Thabane; Gordon H Guyatt Journal: BMJ Date: 2016-09-28
Authors: Alexander A Brescia; G Michael Deeb; Stephane Leung Wai Sang; Daizo Tanaka; P Michael Grossman; Devraj Sukul; Chang He; Patricia F Theurer; Melissa Clark; Francis L Shannon; Stanley J Chetcuti; Shinichi Fukuhara Journal: Circ Cardiovasc Interv Date: 2021-03-15 Impact factor: 6.546